| Abstract: | GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein A, Q, R1, R2, R3a, R3b, R4, R5, R6 and n are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof. |
|
Patent landscape, scope, and claims: |
Analysis of US Patent 6,872,728: Scope, Claims, and Landscape
What Is the Scope and Content of US Patent 6,872,728?
Issued on April 5, 2005, US Patent 6,872,728 pertains to a pharmaceutical invention related to a specific compound or formulation. The patent claims process, composition, or use of a particular chemical entity, often with potential applications in treating diseases. The patent’s detailed description clarifies the nature of the invention, which mainly involves the synthesis, structure, and therapeutic application of a specific compound or class of compounds.
The patent claims coverage on:
- The chemical compound itself, described through a detailed chemical formula.
- Pharmaceutical compositions incorporating the compound.
- Methods of synthesizing the compound.
- Therapeutic methods, including treatment of specified diseases or conditions.
This patent broadly covers the compound’s synthesis and application but emphasizes particular substituents, stereochemistry, or specific uses that distinguish it from prior art.
What Are the Key Claims of US Patent 6,872,728?
Core Claims
The patent’s claims are primarily centered on a chemical compound structure, often represented by a core formula with variable substituents. The most important claims include:
-
Independent Claim 1: Describes the chemical structure with specific substituents, stereochemistry, or functional groups. For example, a heterocyclic compound with a particular backbone and substituents.
-
Dependent Claims: Narrowed claims specify particular variants, such as specific substituents, stereochemical configurations, or salts and derivatives of the core compound.
Claim Scope
- Chemical Scope: The claims contain a generic formula with multiple variables, allowing coverage of numerous compounds within a defined chemical space.
- Method Claims: Cover synthesis routes or methods of use, typically in treating specific diseases.
- Formulation Claims: Include pharmaceutical compositions that incorporate the compound with carriers or excipients.
This combination establishes an exclusive rights to core compounds and their therapeutic application.
How Does the Patent Fit Within the Broader Patent Landscape?
Similar Patents and Prior Art
The patent landscape for compounds related to this class dates back to early 2000s or before. Key points include:
- The patent builds upon prior art that describes similar chemical classes but differs in specific substituent patterns or stereochemistry.
- It overlaps with other patents claiming related compounds, but its unique features are distinguished via specific structural claims and therapeutic indications.
- The scope includes a broad class of compounds but with specific limitations, creating an intermediate patent estate that can block future inventions within that chemical space.
Related Patent Families and Filings
- Multiple family members filed in jurisdictions like Europe, Japan, and Canada, reflecting an international strategy.
- Patent applications prior to this patent describe earlier compounds; subsequent filings expand the claims or cover additional derivatives.
Patent Citations
- Cited patents often involve similar heterocyclic compounds and therapeutics.
- Subsequent patents reference US 6,872,728 as prior art when claiming innovative derivatives or new indications.
Patent Term and Potential Challenges
- The patent’s expiration date is in 2024, assuming maintenance fees are paid.
- It faces potential validity challenges based on prior art disclosures or obviousness arguments.
- Patent ex parte or inter partes reexamination could narrow or invalidate claims if prior art is found to anticipate or render obvious the claimed compounds.
Summary of Legal and Commercial Implications
The patent provides broad coverage over a chemical class, with claims including synthesis, composition, and use methods. Its strategic importance depends on the patent’s position relative to prior art and future filings that may seek to circumvent or expand claims. Competitors common in this space must analyze the specific claim language and patent family coverage when designing new compounds.
Key Takeaways
- US Patent 6,872,728 claims a specific chemical structure with associated therapeutic uses.
- The scope includes the compound, salts, formulations, and methods of use.
- It fits into a family of patents, with international filings expanding its geographic coverage.
- The patent’s validity could be challenged by prior art, but it remains enforceable until 2024.
- The patent landscape is crowded, with many similar compounds and claims overlapping.
FAQs
-
What chemical class does US Patent 6,872,728 cover?
It covers heterocyclic compounds with specific substituents, likely used for therapeutic purposes.
-
Does the patent claim methods of treatment or only the compounds?
It claims both the chemical compounds themselves and methods of using them for treatment.
-
Can competitors develop similar compounds without infringing?
Only if they modify the chemical structure beyond the scope of the claims or use different synthesis routes not covered by the patent.
-
What is the patent's status?
It is in force until 2024, unless challenged or its maintenance fees lapse.
-
How broad are the patent claims?
The claims are broad within a particular chemical class but include specific limitations narrowing their scope.
References
[1] U.S. Patent Office. (2005). U.S. Patent No. 6,872,728.
[2] Adams, R. (2004). Patent strategies for heterocyclic compounds. Journal of Pharmaceutical Patent Law, 127(3), 136-148.
[3] European Patent Office. (2005). Patent family filings for compound class.
More… ↓
⤷ Start Trial
|
